Kisspeptin-10
Synthetic C-terminal decapeptide (metastin 45-54) of the natural human KISS1 gene product. High-affinity agonist at the G-protein coupled receptor GPR54 (KISS1R) on hypothalamic GnRH neurons; powerfully triggers pulsatile GnRH release and downstream pituitary LH/FSH secretion. Investigated for hypogonadism, hypothalamic amenorrhea, and assisted reproduction. Not approved by US FDA; prohibited in sports by WADA (S2).
60-Second Scientific Briefing
Kisspeptin-10 is an endogenous 10-amino-acid C-terminal cleavage fragment of kisspeptin-54 (encoded by KISS1). It binds the KISS1 receptor (KISS1R / GPR54) on hypothalamic GnRH neurons to stimulate pulsatile gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and testosterone secretion. It is an unapproved research peptide.
What is Kisspeptin-10?
Pharmacological Classification & Molecular IdentityEndogenous decapeptide amidated at the C-terminus representing the minimal active sequence of the human KISS1 gene product.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Activates hypothalamic GPR54 receptors, triggering intracellular Gq/11 signaling and stimulating GnRH release into the hypophyseal portal circulation.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA for commercial medical therapy or male testosterone replacement. Research chemical only.
Kisspeptin-10 is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesInvestigated in academic human clinical physiology studies demonstrating acute and multi-day stimulation of LH pulse frequency and testosterone secretion in healthy men.
Clinical Evidence
Investigated in academic human clinical physiology studies demonstrating acute and multi-day stimulation of LH pulse frequency and testosterone secretion in healthy men.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesShort-term clinical administration reported to be generally well-tolerated with occasional localized injection site reactions, mild headache, and flushing.
Potential for pituitary/hypothalamic receptor down-regulation, desensitization, or suppression of the HPG axis with chronic unmonitored use.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED. No approved clinical prescription dosage exists.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Endogenous decapeptide amidated at the C-terminus representing the minimal active sequence of the human KISS1 gene product.
- Targets & Selectivity: Activates hypothalamic GPR54 receptors, triggering intracellular Gq/11 signaling and stimulating GnRH release into the hypophyseal portal circulation.
- Investigated in academic human clinical physiology studies demonstrating acute and multi-day stimulation of LH pulse frequency and testosterone secretion in healthy men.
- Safety considerations: Short-term clinical administration reported to be generally well-tolerated with occasional localized injection site reactions, mild headache, and flushing.
? Unknown / Under Ongoing Investigation
- Potential for pituitary/hypothalamic receptor down-regulation, desensitization, or suppression of the HPG axis with chronic unmonitored use.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysKisspeptin-10 is classified as a KISS1 Receptor (KISS1R / GPR54) Agonist. Molecular structure: Endogenous decapeptide amidated at the C-terminus representing the minimal active sequence of the human KISS1 gene product..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Kisspeptin-10 exerts biological activity via Activates hypothalamic GPR54 receptors, triggering intracellular Gq/11 signaling and stimulating GnRH release into the hypophyseal portal circulation..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Regulatory status: Not approved by the US FDA for commercial medical therapy or male testosterone replacement. Research chemical only.
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Clinical evaluation status: Investigated in academic human clinical physiology studies demonstrating acute and multi-day stimulation of LH pulse frequency and testosterone secretion in healthy men.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Reported safety profile: Short-term clinical administration reported to be generally well-tolerated with occasional localized injection site reactions, mild headache, and flushing.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Key scientific uncertainties: Potential for pituitary/hypothalamic receptor down-regulation, desensitization, or suppression of the HPG axis with chronic unmonitored use.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
NOT ESTABLISHED. No approved clinical prescription dosage exists.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Storage status: NOT ESTABLISHED for commercial distribution. Laboratory storage requires -20°C.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (European Journal of Endocrinology, 2026-08-03)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesFDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) ↗
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men ↗
https://doi.org/10.1093/ejendo/lvag134